PPARγ, the ultimate thrifty gene

Diabetologia

Volumn 42, Issue 9, 1999, Pages 1033-1049

  Auwerx, J ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Adipogenesis; Adipose tissue; Cofactors; Fatty acids; Gene expression; Insulin resistance; Nuclear receptors; Prostaglandin; Thiazolidinediones; Transcription; Type II diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; CELL RECEPTOR; INSULIN;

ADIPOSE TISSUE; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; CELL CYCLE; ENERGY METABOLISM; GENETICS; MICROBODY; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; CELL CYCLE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HUMANS; INSULIN; MICROBODIES; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0032588487     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051268     Document Type: Review

References (191)

1. Desvergne B, Wahli W (1994) In: Bauerle P (ed) Inducible gene expression. Birkhauser, Basel pp 142-176
2. Schoonjans K, Marin G, Staels B, Auwerx J (1997) Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8: 159-165
3. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R et al. (1997) Organization, promoter analysis and expression of the human PPARγ gene. J Biol Chem 272: 18779-18789
4. Greene ME, Blumberg B, McBride OW et al. (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA:expression in hematopoietic cells and chromosomal mapping. Gene Expr 4: 281-299
5. Vigouroux C, Fajas L, Khallouf E et al. (1998) Human peroxisome proliferator-activated receptor gamma 2:genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsable for lipoatrophic diabetes. Diabetes 47: 490-492
6. Zhu Y, Qi C, Korenberg JR et al. (1995) Structural organization of mouse peroxisome proliferator activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc Natl Acad Sci USA 92: 7921-7925
7. Fajas L, Fruchart JC, Auwerx J (1998) PPARγ3 mRNA:a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett 438: 55-60
8. Schoonjans K, Staels B, Auwerx J (1996) Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 907-925
9. Nolte RT, Wisely GB, Westin S et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor γ. Nature 395: 137-143
10. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A (1998) Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ. J Biol Chem 273: 31108-31112
11. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W (1992) Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68: 879-887
12. Auboeuf D, Rieusset J, Fajas L et al. (1997) Tissue distribution and quantification of the expression of PPARs and LXRα in humans: no alterations in adipose tissue of obese and NIDDM patients. Diabetes 48: 1319-1327
13. Ricote M, Huang J, Fajas L et al. (1998) Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95: 7614-7619
14. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. (1997) Peroxisome proliferator-activated receptor gene expression in human tissues:effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99: 2416-2422
15. Vidal-Puig A, Jimenez-Linan M, Lowell BB et al. (1996) Regulation of PPARγ gene expression by nutrition and obesity in rodents. J Clin Invest 97: 2553-2561
16. Lefebvre AM, Laville M, Vega N et al. (1998) Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47: 98-103
17. Rieusset J, Andreelli D, Auboeuf D et al. (1999) Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor γ in human adipocytes. Diabetes 48: 699-705
18. Xing H, Northrop JP, Grove JR, Kilpatrick KE, Su JL, Ringold GM (1997) TNFα-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARγ without effects on Pref-1 expression. Endocrinology 138: 2776-2783
19. Hill M, Young M, McCurdy C, Gimble J (1997) Decreased expression of murine PPARγ in adipose tissue during endotoxinemia. Endocrinology 138: 3073-3076
20. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM (1998) Skeletal muscle peroxisome proliferator-activated receptor-γ expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 101: 543-548
21. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR (1997) PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 46: 1230-1234
22. Park KS, Ciaraldi TP, Lindgren K et al. (1998) Troglitazone effects on muscle gene expression in human skeletal muscle of Type II diabetes involve up-regulation of peroxisome proliferator-activated receptor γ. J Clin Endocrinol Metab 83: 2830-2835
23. Spiegelman BM, Flier JS (1996) A dipogenesis and obesity: rounding out the big picture. Cell 87: 377-389
24. Fajas L, Fruchart JC, Auwerx J (1998) Transcriptional control of adipogenesis. Curr Opin Cell Biol 10: 165-173
25. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147-1156
26. Hu E, Tontonoz P, Spiegelman BM (1995) Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα. Proc Natl Acad Sci USA 92: 9856-9860
27. Yeh WC, Cao Z, Classon M, McKnight S (1995) Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev 9: 168-181
28. Wu Z, Xie Y, Bucher NLR, Farmer SR (1995) Conditional ectopic expression of C/EBPβ in NIH-3T3 cells induces PPARγ and stimulates adipogenesis. Genes Dev 9: 2350-2363
29. Wu Z, Bucher NLR, Farmer SR (1996) Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/ EBPβ, C/EBPδ, and glucocorticoids. Mol Cell Biol 16: 4128-4136
30. Saladin R, Fajas L, Dana S, Halvorsen YD, Auwerx J, Briggs M (1999) Differential regulation of peroxisome proliferator activated receptor γ1 (PPARγ1) and PPARγ2 mRNA expession in early stages of adipogenesis. Cell Growth Differ 10: 43-48
31. DiRenzo J, Soderstrom M, Kurokawa R et al. (1997) Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors. Mol Cell Biol 17: 2166-2176
32. Xue JC, Schwarz EJ, Chawla A, Lazar MA (1996) Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARγ. Mol Cell Biol 16: 1567-1575
33. Tontonoz P, Kim JB, Graves RA, Spiegelman BM (1993) ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol Cell Biol 13: 4753-4759
34. Kim JB, Spiegelman BM (1996) ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 10: 1096-1107
35. Wu Z, Rosen ED, Brun R et al. (1999) Cross-regulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol. Cell 3: 143-150
36. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPARγ2:tissue-specific regulator of an adipocyte enhancer. Genes Dev 8: 1224-1234
37. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM (1995) PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15: 351-357
38. Schoonjans K, Staels B, Grimaldi P, Auwerx J (1993) AcylCoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur J Biochem 216: 615-622
39. Martin G, Schoonjans K, Lefebvre A, Staels B, Auwerx J (1997) Coordinate regulation of the expression of the fatty acid transport protein (FATP) and acyl CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 272: 28210-28217
40. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM et al. (1996) PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15: 5336-5348
41. Schoonjans K, Martin G, Staels B, Auwerx J (1997) Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8: 159-166
42. Auwerx J, Staels B (1998) Leptin. Lancet 351: 737-742
43. De Vos P, Lefebvre AM, Miller SG et al. (1996) Thiazolidinediones repress ob gene expression via activation of PPARγ. J Clin Invest 98: 1004-1009
44. Zhang B, Graziano MP, Doebber TW et al. (1996) Down-regulation of the expression of the obese gene by antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 271: 9455-9459
45. Kallen CB, Lazar MA (1996) Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocvtes. Proc Natl Acad Sci USA 93: 5793-5796
46. Miller SG, De Vos P, Guerre-Millo M et al. (1996) The adipocyte specific transcription factor, C/EBPα modulates human ob gene expression. Proc Natl Acad Sci USA 93: 5507-5511
47. He Y, Chen H, Quon MJ, Reitman M (1995) The mouse obese gene. Genomic organization, promoter activity, and activation by CCAAT/enhancer-binding protein alpha. J Biol Chem 270: 28887-28891
48. Hollenberg AN, Susulic VS, Madura JP et al. (1997) Functional antagonism between CCAAT/enhancer binding protein-α and peroxisome proliferator-activated receptor-γ on the leptin promoter. J Biol Chem 272: 5283-5290
49. Torti FM, Dieckman B, Beutler B, Cerami A, Ringold GM (1985) A macrophage factor inhibits adipocyte gene expression; an in vitro model for cachexia. Science 229: 867-869
50. Beutler B, Cerami A (1988) Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response. Endocr Rev 9: 57-66
51. Williams PM, Chang DJ, Danesch U, Ringold GM, Heller RA (1992) CCAAT/enhancer binding protein expression is rapidly extinguished in TA1 adipocyte cells treated with tumor necrosis factor. Mol Endocrinol 6: 1135-1141
52. Ron D, Brasier AR, McGehee REJ, Habener JF (1992) Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). J Clin Invest 89: 223-233
53. Peraldi P, Xu M, Spiegelman BM (1997) Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signalling. J Clin Invest 100: 1863-1869
54. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose tissue expression of tumor necrosis factor-α:direct role in obesity-linked insulin resistance. Science 259: 87-91
55. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity induced insulin resistance. Science 271: 665-668
56. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM (1994) Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 91: 4854-4858
57. Okuno A, Tamemoto H, Tobe K et al. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101: 1354-1361
58. Hofmann C, Lorenz K, Braithwaite SS et al. (1994) Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 134: 264-270
59. Souza SC, Yamamoto MT, Franciosa MD, Lien P, Greenberg AS (1998) BRL 49653 blocks lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes 47: 691-695
60. Hallakou S, Doare L, Foufelle F et al. (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46: 1393-1399
61. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995) 15-Deoxy-Δ12, 14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83: 803-812
62. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehman JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83: 813-819
63. Krey G, Braissant O, L'Horset F et al. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by co-activator-dependent receptor ligand assay. Mol Endocrinol 11: 779-791
64. Ma H, Sprecher HW, Kolattukudy PE (1998) Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in PPARγ-expressing tissue. J Biol Chem 273: 30131-30138
65. Kliewer SA, Sundseth SS, Jones SA et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 94: 4318-4323
66. Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 94: 4312-4317
67. Nagy L, Tontonez P, Alvarez JG, Chen H, Evans RM (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93: 229-240
68. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252
69. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ). J Biol Chem 270: 12953-12956
70. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410
71. Berger J, Bailey P, Biswas C et al. (1996) Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137: 4189-4195
72. Willson TM, Cobb JE, Cowan DJ et al. (1996) The structure activity relationship between peroxisome proliferator activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668
73. Mukherjee R, Davies PAJ, Crombie DL et al. (1997) Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386: 407-410
74. Murakami K, Tobe K, Ide T et al. (1998) A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor α and γ. Effect of PPARα activation on normal lipid metabolism in liver of Zucker fatty rats. Diabetes 47: 1841-1847
75. Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K (1999) Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidininedione derivative. Eur J Pharmacol 364: 211-219
76. Lefebvre A-M, Peinado-Onsurbe J, Leitersdorf I et al. (1997) Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 17: 1756-1764
77. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G et al. (1999) Novel peroxisome proliferator activated receptor (PPAR) γ and PPARδ ligands produce disinct biological effects. J Biol Chem 274: 6718-6725
78. Moller DE, Flier JS (1991) Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 325: 938-948
79. Shimomura I, Hammer RE, Richardson JA et al. (1998) Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1 c in adipose tissue:a model for congenital generalized lipodystrophy. Genes Dev 12: 3182-3194
80. Moitra J, Mason MM, Olive M et al. (1998) Life without fat: a transgenic mouse. Genes Dev 12: 3168-3181
81. Shimomura I, Funahashi T, Takahashi M et al. (1996) Enhanced expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity. Nat Med 2: 800-803
82. Cohen B, Novick D, Rubinstein M (1996) Modulation of insulin activities by leptin. Science 274: 1185-1188
83. Muller G, Ertl J, Gerl M, Preibisch G (1997) Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 272: 10585-10593
84. Liu YL, Emilson V, Cawthorne MA (1997) Leptin inhibits glycogen synthesis in isolated soleus muscle of obese (ob/ob) mice. FEBS Lett 411: 351-355
85. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ (1997) Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389: 374-377
86. Rosen B, Cook KS, Yaglom J et al. (1989) Adipsin and complement factor D activity: an immune-related defect in obesity. Science 244: 1483-1487
87. Frederich RC, Kahn BB, Peach MJ, Flier JS (1992) Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 19: 339-344
88. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1 q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749
89. Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697-10703
90. Randle PJ, Garland PB, Hales CN, Newsholme EA (1961) The glucose-fatty acid cycle:its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. Lancet I: 785-789
91. Martin G, Schoonjans K, Staels B, Auwerx J (1998) PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 137: 75-80
92. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW (1997) The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue availability in the rat. Metabolism 46: 935-942
93. Ribon V, Johnson JH, Camp HS, Saltiel AR (1998) Thiazolidinediones and insulin resistance:peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA 95:14751-14756
94. Burant CF, Sreenan S, Hirano K-I et al. (1997) Troglitazone action is independent of adipose tissue. J Clin Invest 100: 2900-2908
95. Bouchard C, Perusse L (1993) Genetics of obesity. Annu Rev Nutrition 13: 337-354
96. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432
97. Tartaglia LA, Dembski M, Weng X et al. (1995) Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-1271
98. Montague CT, Farooqi IS, Whitehead JP et al. (1997) Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387: 903-908
99. Clément K, Vaisse C, Lahlou N et al. (1998) A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392: 398-401
100. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR (1998) Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339: 953-959
101. Deeb S, Fajas L, Nemoto M, Laakso M, Fujimoto W, Auwerx J (1998) A Pro 12 Ala substitution in the human peroxisome proliferator-activated receptor gamma2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nat Genet 20: 284-287
102. Beamer BA, Yen CJ, Andersen RE et al. (1998) Association of the Pro12Ala variant in peroxisome proliferator-activated receptor gamma2 gene with obesity in two Caucasian populations. Diabetes 47: 1806-1808
103. Yen CJ, Beamer BA, Negri C et al. (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians:identification of a Pro12Ala PPARgamma 2 missense mutation. Biochem Biophys Res Commun 241: 270-274
104. Hu E, Kim JB, Sarraf P, Spiegelman BM (1996) Inhibition of adipogenesis through MAP-kinase mediated phosphorylation of PPARγ. Science 274: 2100-2103
105. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK (1997) Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272: 5128-5132
106. Camp HS, Tafuri SR (1997) Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 272: 10811-10816
107. Zhang B, Berger J, Zhou G et al. (1996) Insulin and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 271: 31771-31774
108. Norman RA, Thomp-son DB, Foroud T et al. (1997) Genomewide search for genes influencing percent body fat in Pima indians:suggestive linkage at chromosome 11Q21 Q22. Am J Hum Genet 60: 166-173
109. Mori Y, Kim-Motoyama H, Katakura T et al. (1998) Effect of the Pro12Ala variant of the human peroxisome proliferator activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 251: 195-198
110. Hara H, Egusa G, Yamakido M (1996) Incidence of non-insulin-dependent diabetes mellitus and its risk factors in Japanese-Americans living in Hawai and Los Angeles. Diabet Med 13:[suppl] S133-S142
111. EK J, Urhammer SA, Sorensen FIA, Anderson T, Anwerx J, Pedersen O (1999) Homozygosity of the Pro12Ala variant of the peroxisome proliferator activated receptor Y2 (PPARγ 2): Divergent modulating effects on body mass index in obese and lean men of Caucasian origin. Diabetologia 42: 892-895
112. Werman A, Hollenberg A, Solanes G, Bjorbaek C, VidalPuig A, Flier JS (1997) Ligand-independent activation domain in the N terminus of peroxisome proliferatoractivated receptor γ (PPARγ). J Biol Chem 272: 20230-20235
113. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA (1998) Interdomain communication regulating ligand binding by PPAR gamma. Nature 396: 377-380
114. Schoonjans K, Staels B, Auwerx J (1996) The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93-109
115. Staels B, Vu-Dac N, Kosykh V et al. (1995) Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal Acyl Co-enzyme A Oxidase. J Clin Invest 95: 705-712
116. Hertz R, Bishara-Shieban J, Bar-Tana J (1995) Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III. J Biol Chem 270: 13470-13475
117. Castle CK, Colca JR, Melchior GW (1993) Lipoprotein profile characterization of the KKAy mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler Thromb 13: 302-309
118. Schwartz S, Raskin P, Fonseca V, Graveline JF (1998) Effect of troglitazone in insulin-treated patients with type II diabetes. N Engl. J Med 338: 861-866
119. Kumar S, Boulton AJM, Beck-Nielsen H et al. (1996) Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39: 701-709
120. Ghazzi MN, Perez JE, Antonucci TK et al. (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46: 433-439
121. Berthezene F (1996) Non-insulin dependent diabetes and reverse cholesterol transport. Atherosclerosis 124 [Suppl]: S39-S42
122. Sasahara T, Yamashita T, Sviridov D, Fidge N, Nestel P (1997) Altered properties of high density lipoprotein subfractions in obese subjects. J Lipid Res 38: 600-611
123. Glass CK, Rose DW, Rosenfeld MG (1997) Nuclear receptor coactivators. Curr Opin Cell Biol 9: 222-232
124. Abraham SE, Lobo S, Yaciuk P, Heidi HG, Moran E (1993) p300 and p300-associated proteins, are components of the TATA-binding protein (TBP) complexes. Oncogene 8: 1639-1647
125. Nakajima T, Uchida C, Anderson S et al. (1997) RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90: 1107-1112
126. Fraser RA, Rossignol M, Heard DJ, Egly JM, Chambon P (1997) SUG1, a putative transcriptional mediator and subunit of the PA700 proteasome regulatory complex, is a DNA helicase. J Biol Chem 272: 7122-7126
127. Fraser RA, Heard DJ, Adam S et al. (1998) The putative cofactor TIF1alpha is a protein kinase that is hyperphosphorylated upon interaction with liganded nuclear receptors. J Biol Chem 273: 16199-16204
128. Bannister AJ, Kouzarides T (1996) The CBP co-activator is a histone acyltransferase. Nature 384: 641-643
129. Chen H, Lin RJ, Louis Schiltz L et al. (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms multimeric activation complexes with P/CAF and CBP/p300. Cell 90: 569-580
130. Korzus E, Torchia J, Rose DW et al. (1998) Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279: 703-707
131. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959
132. Spencer TEJ, Burcin MM, Allis CD et al. (1997) Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389: 194-198
133. Martinez-Balbas MA, Bannister AJ, Martin K, HausSeuffert P, Meisterernst M, Kouzarides T (1998) The acetyltransferase activity of CBP stimulates transcription. EMBO J 17: 2886-2893
134. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H (1997) Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 7: 689-692
135. Nagy L, Kao HK, Chakravarti D et al. (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3 A, and histone deacetylase. Cell 89: 373-380
136. Alland L, Muhle R, Hou H et al. (1997) Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387: 49-55
137. Heinzel T, Lavinsky RM, Mullen TM et al. (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387: 43-48
138. Pazin MJ, Kadonaga JT (1997) What's up and down with histone deacetylation and transcription? Cell 89: 325-328
139. Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377: 454-457
140. Chen DJ, Umesono K, Evans RM (1996) SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc Natl Acad Sci USA 93: 7567-7571
141. Lavinsky RM, Jepsen K, Heinzel T et al. (1998) Diverse signalling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920-2925
142. Zamir I, Zhang J, Lazar M (1997) Stochiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev 11: 835-846
143. Misiti S, Schomburg L, Yen PM, Chin WW (1998) Expression and hormonal regulation of co-activator and corepressor genes. Endocrinology 139: 2493-2500
144. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH (1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365: 855-859
145. Eckner R, Ewen ME, Newsome D et al. (1994) Molecular cloning and functional analysis of the adenovirus E1A-associated 300 kD protein (p300) reveals a protein with properties of a transcriptional adaptator. Genes Dev 8: 869-884
146. Janknecht R, Hunter T (1996) Transcriptional control: versatile molecular glue. Curr Biol 6: 951-954
147. Chakravarti D, LaMorte VJ, Nelson MC et al. (1996) Role of CBP/p300 in nuclear receptor signalling. Nature 383: 99-103
148. Kamei Y, Xu L, Heinzel T et al. (1996) A CBP Integrator Complex Mediates Transcriptionnal Activation and AP-1 Inhibition by Nuclear Receptors. 85: 403-414
149. Hanstein B, Eckner R, DiRenzo J et al. (1996) p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 93: 11540-11545
150. Smith CL, Onate SA, Tsai MJ, O'Malley BW (1996) CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 93: 8884-8888
151. Kraus WL, Kadonaga JT (1998) p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev 12: 331-342
152. Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M (1997) p300 functions as a co-activator for the peroxisome proliferator-activated receptor α. J Biol Chem 272: 33433-33435
153. Gelman L, Zhou G, Fajas L, Raspe E, Fruchart JC, Auwerx J (1999) p300 interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner respectively. J Biol Chem 274: 7681-7688
154. Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional coactivators mediates binding to nuclear receptors. Nature 387: 733-736
155. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H (1998) The coactivator TIF2 contains three nuclera receptor binding motifs and mediates transcativation through CBP binding-dependent and -independent pathways. EMBO J 17: 507-519
156. Onate SA, Tsai SY, Tsai MJ, O'Malley BW (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354-1357
157. Zhu Y, Qi C, Calandra C, Rao MS, Reddy J (1996) Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor γ. Gene Expr 6: 185-195
158. Zhou G, Cummings R, Li Y et al. (1998) Nuclear receptors have distinct affinities for coactivators:characterization by fluorescence resonance energy transfer. Mol Endocrinol 12: 1594-1604
159. McInermey E, Rose D, Flynn S et al. (1998) Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev 12: 3357-3368
160. Zhu Y, Qi C, Rao MS, Reddy JK (1997) Isolation of and characterization of PBP, a protein that interacts with peroxisome proliferator activated receptor. J Biol Chem 272: 25500-25506
161. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829-839
162. Jain S, Pulikuri S, Zhu Y et al. (1998) Differential expression of the peroxisome proliferator-activated receptor γ (PPARγ) and its coactivators steroid receptor coactivator1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 153: 349-354
163. Serhan CN, Haeggstrom JZ, Leslie CC (1996) Lipid mediator networks in cell signaling:update and impact of cytokines. FASEB Journal 10: 1147-1158
164. Jiang C, Ting AT, Seed B (1998) PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86
165. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature 391: 79-82
166. Colville-Nash PR, Qureshi SS, Willis D, Willoughby DA (1998) Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists:correlation with induction of heme oxygenase. J Immunol 161: 978-984
167. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J (1998) Macrophages in human atheroma contain PPARgamma: differentiation-dependent PPARgamma expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 153: 17-23
168. Marx N, Schoenbeck U, Lazar MA, Libby P, Plutzky J (1998) Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83: 1097-1103
169. Shao D, Lazar MA (1997) Peroxisome proliferator activated receptor γ, CCAAT/enhancer binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 272: 21473-21478
170. Hansen JB, Petersen RK, Larsen BM, Bartkova J, Alsner J, Kristiansen K (1999) Activation of peroxisome proliferator activated receptor γ bypasses the function of the retinoblastoma protein in adipocyte differentiation. J Biol Chem 274: 2386-2393
171. Altiok S, Xu M, Spiegelman B (1997) PPARγ induces cell cycle withdrawal:inhibition of E2F/DP DNA-binding activity via down-regulation of PP2 A. Genes Dev 11: 1987-1998
172. Tontonoz P, Singer S, Forman BM et al. (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94: 237-241
173. Elstner E, Muller C, Koshizuka K et al. (1998) Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806-8811
174. Mueller E, Sarraf P, Tontonoz P et al. (1998) Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1: 465-470
175. Brockman JA, Gupta RA, DuBois RN (1998) Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115: 1049-1055
176. Kuboto T, Koshizuka K, Williamson IA et al. (1998) Ligand for peroxisome proliferator activated receptor γ (troglitazone) has potent anti-tumor effects against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352
177. Gimble JM, Pighetti GM, Lerner MR et al. (1998) Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic mammary glands. Biochem Biophys Res Commun 253: 813-817
178. Min/+ mice. Nature Med 4: 1053-1057
179. Saez E, Tontonoz P, Nelson MC et al. (1998) Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Med 4: 1058-1061
180. Su LK, Kinzler KW, Vogelstein B et al. (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668-670
181. Groden J, Thliveris A, Samowitz W et al. (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 589-600
182. Powell SM, Petersen GM, Krush AJ et al. (1993) Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 329: 1982-1987
183. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA (1996) Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 222: 844-851
184. Kinzler KW, Vogelstein B (1996) Lessons from heriditary colorectal cancer. Cell 87: 159-170
185. Thun MJ, Namboodiri MM, Heath CW (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596
186. Oshima M, Dinchuk JE, Kargman SL et al. (1996) Suppression of intestinal polyposis in APCΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809
187. Giovanucci E, Willet WC (1994) Dietary factors and risk of colon cancer. Ann Med 26: 443-452
188. Wasan HS, Novelli M, Bee J, Bodmer WF (1997) Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc Natl Acad Sci USA 94: 3308-3313
189. Sarraf P, Mueller E, Jones D, et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052
190. Anzick SL, Kononen J, Walker RL et al. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968
191. Watkins PB, Whitcomb RW (1998) Hepatic dysfunction assocaited with troglitazone. N Engl J Med 338: 916-91